Eiger BioPharmaceuticals, Inc.: going-concern / distress — Eiger BioPharmaceuticals Chapter 11 liquidation plan effective; common stock cancelled

Eiger BioPharmaceuticals, Inc.

September 30, 2024 effective date: all outstanding common shares cancelled and no longer valid.
Equity holders entitled to pro rata share of Existing Equity Interest Recovery Pool, if any.
Company intends to file Form 15 to immediately suspend SEC reporting obligations.
Plan confirmed by Bankruptcy Court on September 5, 2024; earlier Chapter 11 filing on April 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Distress & Bankruptcy SEC 8-K Item 1.03 confidence 0.9

Eiger BioPharmaceuticals, Inc. entered chapter 11 in United States Bankruptcy Court for the Northern District of Texas (petition 2024-04-01).

Proceeding: chapter 11
Court: United States Bankruptcy Court for the Northern District of Texas
Petition: 2024-04-01

Exact text from the filing

on April 1, 2024, Eiger BioPharmaceuticals, Inc. (the “ Company ”) and its direct subsidiaries (together the “ Debtors ”) filed voluntary petitions for relief under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Northern District of Texas (the “ Bankruptcy Court ”) under the caption In re Eiger BioPharmaceuticals, Inc., et al , Case No. 24-80040.

View on SEC.gov

Browse all distress & bankruptcy →

Source: SEC EDGAR

accession 0001193125-24-229453

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.